Windlas Biotech Ltd reports Q2 FY27 revenue of ₹264 crore, up 19% YoY, and adjusted PAT of ₹25 crore, up 29%.
- Q2 adjusted EBITDA rose 20% to ₹36 crore, with a 13.7% margin; adjusted PAT margin was 9.5%.
- Reported Q2 EBITDA and PAT were ₹29 crore and ₹18 crore, respectively, after ₹7 crore of non-cash ESOP expenses.
- H1 FY27 revenue increased 18% to ₹512 crore; adjusted EBITDA rose 23% to ₹70 crore and adjusted PAT 33% to ₹50 crore.